Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs

Trial Profile

A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Nov 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Baricitinib (Primary) ; Folic acid; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms RA-BEGIN
  • Sponsors Eli Lilly and Company
  • Most Recent Events

    • 17 Nov 2020 Results of pooled analysis of data pooled from 3 studies ( RA BEGIN, RA BEAM and one ongoing long term extension (RA BEYOND) assessing long term efficacy of once daily Baricitinib in patients with active Rheumatoid arthritis who were either naive to DMARDs or who had inadequate response to MTX, published in the Rheumatology
    • 06 Jun 2020 Results of post-hoc analysis assessing long-term efficacy of Baricitinib in patients with active rheumatoid arthritis from two phase3 clinical studies: RA-BEGIN and RA-BEAM and one long-term extension study RA-BEYOND presented at the 21st Annual Congress of the European League Against Rheumatism
    • 15 Jun 2019 Results presented at the 20th Annual Congress of the European League Against Rheumatism
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top